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Yor1p, a Saccharomyces cerevisiae plasma membrane ABC-transporter, is associated to oligomycin resistance and to rhodamine B transport.
Here, by using the overexpressing strain Superyor [A. Decottignies, A.M. Grant, J.W. Nichols, H. de Wet, D.B. McIntosh, A. Goffeau, ATPase
and multidrug transport activities of the overexpressed yeast ABC protein Yor1p, J. Biol. Chem. 273 (1998) 12612–12622], we show that Yor1p
also confers resistance to rhodamine 6G and to doxorubicin. In addition, Yor1p protects cells, although weakly, against tetracycline, verapamil,
eosin Yand ethidium bromide. The basal ATPase activity of the overexpressed form of Yor1p was studied in membrane preparations. This activity
is quenched upon addition of micromolar amounts of vanadate. Vmax and Km values of ∼0.8 s−1 and 50±8 μM are measured. Mutations of
essential residues in the nucleotide binding domain 2 reduces the activity to that measured with a Δyor1 strain. ATP hydrolysis is strongly
inhibited by the addition of potential substrates of the transporter. Covalent reaction of 8-azido-[α-32P]ATP with Yor1p is not sensitive to the
presence of excess oligomycin. Thus, competition of the drug with ATP binding is unlikely. Finally, we inspect possible hypotheses accounting for
substrate inhibition, rather than stimulation, of ATP hydrolysis by the membrane preparation.
© 2007 Elsevier B.V. All rights reserved.Keywords: Yor1p; ABC transporter; Plasma membranes; ATPase activity1. Introduction
Most ATP-binding cassette (ABC) proteins mediate ATP-
driven selective transport of a wide range of substrates across
biological membranes [1–3]. In accordance with their common
function, ABC-transporters share a conserved structural archi-
tecture consisting of two homologous halves, each containing a
transmembrane domain (TMD) and a nucleotide binding
domain (NBD). The TMDs harbor the substrate binding sitesAbbreviations: ABC, ATP binding cassette; TMD, Transmembrane domain;
NBD, Nucleotide binding domain; P-gp, P-glycoprotein; CFTR, Cystic fibrosis
transmembrane conductance regulator; MRP, Multidrug resistance associated
protein; p-CMPS, p-chloromercuriphenylsulfonate; DCC, N,N'-di-cyclohexyl-
carbodiimide; NEM, N-ethylmaleimide; DTT, 1–4 dithiothreitol; BSA, Bovine
serum albumine; EDTA, Ethylenediaminetetraacetic acid; PNK, Polynucleotide
5′-hydroxyl-kinase; MIC, Minimal inhibitory concentration
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doi:10.1016/j.bbamem.2007.08.035and the NBDs couple the energy of ATP hydrolysis to transport.
The NBDs share extensive amino acid sequence identities and
characteristic motifs, the Walker A and Walker B, found in
numerous nucleotide binding proteins [4]. Another motif called
the C-loop or signature sequence defines this family [5]. In
addition to these motifs, sequence alignments have highlighted
very conserved residues that define the A-, Q-, D-, and H-loops
[6–8]. Resolution of the crystal structures of various isolated
NBDs and of full transporters shows that the functional unit is a
“head to tail” dimer in which one molecule of ATP is sand-
wiched between the Walker A motif in one monomer and the
signature in the other. The other ATP substrate interacts with the
Walker A motif in the second monomer and the signature of the
first monomer (for review see [8]).
ABC-proteins have been divided into subfamilies based on
similarities in overall protein primary structures, including
relative order of the NBDs and TMDs and amino acid sequence
homologies. Seven mammalian subfamilies have been distin-
guished [9]. The ABCC subfamily includes 13 proteins of great
clinical importance. The CFTR (ABCC7) protein is a chloride
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ABCC8 and ABCC9 proteins bind sulfonylurea and regulate
potassium channels involved in modulating insulin secretion.
The rest of the subfamily is composed of nine or probably ten
multidrug resistance-related genes. Of these, ABCC1 (or
MRP1) has been extensively studied because it is involved in
cancer cell resistance to chemotherapy [10].
In the yeast Saccharomyces cerevisiae, six proteins, homol-
ogous to the ABCC human subfamily members, compose
subclass II.1 [6]. The most studied protein in this subclass is the
yeast cadmium factor (Ycf1p), functionally homologous to
MRP1. Ycf1p is a vacuolar transporter active in heavy metal and
drug detoxification through conjugation to glutathione (GSH)
[11,12]. The structural and functional similarities between the
human and yeast ABCC subfamilies suggest that the latter may
provide useful models to study this particular class of ABC-
transporters.
In the yeast subclass II.1, Yor1p is a plasma membrane
ABC-protein involved in the resistance to oligomycin and to
organic anions such as rhodamine B [13,14]. Transport of
these drugs is obtained at the expense of ATP. Possible
Yor1p UTPase activity has been searched for by Decottignies
et al. [15], but without success. Expression of Yor1p is up-
regulated by the transcription factors Pdr1p and Pdr3p.
Decottignies et al. [15] have shown that, in a Pdr1–3 gain of
function mutant, YOR1 placed under the control of the
PDR5 promoter was constitutively overexpressed. Under this
condition, the YOR1 product reached up to 10% of total
membrane proteins. This property was used to isolate
partially purified protein. In the present study, we used the
expression system described above to further investigate the
properties of Yor1p. We have chosen to study the behaviourTable 1
Oligonucleotides used in this study
Oligonucleotide Sequence
LINKERY1 AATTGAGCTCACTAGTGGCCTT
LINKERY2 CTAGATGCATCCCGGGGCATGC
CYC1DEB CCGGAATTCGCATGCGGGCCGC
CYC1FIN CGCGGATCCATGCATGGCCGCA
YOR1-NOT GGGGCGGCCGCTACATCCTCAG
YOR2 GCTCTAGAATTAGTGATGGTGA
YOR3 CATCACCATCACCATCACTAATT
YOR4 TGAATGAAATGACAAGCAGACA
YOR5 CGAGCTCGAATTCATCGATGTC
YOR6-XHO CGCTCGAGCCAACAGAGCCTG
YOR-EXT-1 CTAGGTCTGGTATTGTGGAAAA
YOR-EXT-2 AGAACAGAGGATCGCATCACCA
YOR-EXT-3 ACCATCACCATCACTAATA
YOR-EXT-4 CTAGTATTAGTGATGGTGATGGT
YOR-EXT-5 GTGATGCGATCCTCTGTTCTCGA
YOR-EXT-6 TTCCACAATACCAGAC
YOR-NOT1 GGGGCGGCCGCGATTCGCAAG
YOR-XBA-XHO GCCTCGAGTCTAGAATTAGTGA
YORINACT1 GTAAGGATACATGGGGTAAGCC
YORINACT4 TTCTTGACTAAACAACGTCCAT
YNBD2MUTEQ1 AAAAATATTGATTTTGGATCAGG
YNBD2MUTEQ2 TCCACTGAGGATGTAGCCTGAT
YNBD2MUTHR1 ACAATTTTGTGTATTGCTCGTAG
YNBD2MUTHR2 TACAATGGTCTTCAGTCTACGAof plasma membrane extracts in order to maintain over-
expressed Yor1p in a native environment.
2. Materials and methods
2.1. Materials
Oligomycin, rhodamine B, rhodamine 6G, doxorubicin, verapamil, tetra-
cycline, fluorescein, aprotinin, leupeptin, pepstatin, benzamidine, ovomucoid,
p-chloromercuriphenylsulfonate (p-CMPS), N,N'-di-cyclohexylcarbodiimide
(DCC), N-ethylmaleimide (NEM), glass beads (acid-washed, 425–600 μm)
and G418 were purchased from Sigma. Sodium orthovanadate was from Acros
Organics. Rhodamine 101, heparin, ouabain, antipain, chymostatin and
o-phenanthroline were from Fluka. Sodium azide and erythrosin B were from
Merck. The “HMW-SDS Calibration Kit” and ATP were from Amersham
Biosciences. [γ-32P]ATP was from Perkin Elmer. 8-azido-[α-32P]ATP was from
MP Biomedicals.
All the oligonucleotides used for gene constructions are listed in Table 1.
Plasmid pSK-PDR5PPUS is described in [15]. pBluescript SK+ and pYES2
were from Stratagene and Invitrogen, respectively.
2.2. Strains and growth media
The S. cerevisiae strain Superyor (MATα, PDR1-3, his1, Δyor1∷hisG,
Δsnq2∷hisG, Δpdr5∷PDR5PROM-YOR1-PDR5STOP, Δpdr10∷hisG,
Δpdr11∷hisG, Δycf1∷hisG, Δpdr3∷hisG) is described in [15]. Cells were
grown at 30 °C in rich YT medium, containing 1% yeast extract (Difco), 1%
Bacto-tryptone (Difco), and either 2% glucose (YT-glucose medium) or 2%
glycerol (YT-glycerol medium), as indicated. Transformations of yeast cells
were performed by the lithium acetate method [16]. Transformants were plated
on YT-glucose plates containing 200 μg/ml G418 to select the KanR marker.
2.3. Construction of the S. cerevisiae strains
2.3.1. Construction of Superyor-Δyor
Disruption of YOR1 was achieved by insertion of the KanR selectable
marker between nucleotides 1751 and 4311 of the YOR1 open reading frame.AAAGGCCCTCGAGGCATGCCCCGGGATGCAT
CTCGAGGGCCTTTAAGGCCACTAGTGAGCTC
ATCATGTAATTAGTTATG
AATTAAAGCCTTCGAGCG
TGGACTAC
TGGTGATGCGATCCTCTGTTCTCGAAATCATT
CTAGAGCGTACGCTGCAGGTCGACG
TCGATGAATTCGAGCTCG
TGCTTGTCATTTCATTCA
AATGAA
TGATTTCG
TCACCATC
GATGGTGATG
AATCATT
AACTTAGATCC
TGGTGATGGTGATGGTGATGGTGATGCGATCCTCTGTTCTCGAAATC
ATCTGCAAGTACTAATAAGGCGAAAAGATTGGCGTACGCTGCAGGTC
GGTGTATCGAATTCTGCGACTTCACCCTTCTCATCGATGAATTCGAG
CTACATCCTCAGTGGA
CCAAAATCAATATTTTT
ACTGAAGACCATTGTA
GCAATACACAAAATTGT
Table 2
Effect of different compounds on the growth of the S. cerevisiae strains
Superyor and Superyor-Δyor
Minimal inhibitory concentration (MIC)
Superyor-Δyor Superyor Resistance factor
Oligomycin 0.3 μM N100 μM N300
Rhodamine B 200 μM 7.5 mM 37.5
Rhodamine 6G 1 μM 200 μM 200
Rhodamine 101 0.25 mM 1 mM 4
Erythrosin B 2 mM 15 mM 7.5
Eosin Y 10 mM 20 mM 2
Fluorescein 30 mM 30 mM 1
Doxorubicin 25 μM 250 μM 10
Tetracycline 10 mM N20 mM N2
Verapamil 0.8 mM 2 mM 2.5
o-Phenanthroline 75 μM 75 μM 1
Ethidium bromide 50 μM 75 μM 1.5
CdCl2 30 μM 30 μM 1
Cells were grown at 30 °C in liquid YT-glucose medium, harvested in the
exponential growth phase, washed and diluted in water, to obtain samples with
optical densities at 650 nm of 1, 0.1 and 0.01, respectively. 5 μl of each sample
were spotted onto YT-glucose plates containing increasing concentrations of the
compounds under study and left to incubate at 30 °C for 2 days (see Fig. 1). In
the case of oligomycin, YT-glycerol plates were used. The MIC for a drug is
defined as the minimal concentration at which no more growth is observed at the
highest concentration of cells. Results of three independent experiments were in
agreement. Screened concentrations around the MIC value did not differ by a
factor more than 2. Thus, if a MIC value was possibly overestimated, the error
cannot exceed 50% of the indicated value (see Materials and methods).
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bases homologous to YOR1 and 15 bases to the marker gene, were used to
amplify the KanR cassette from plasmid pFA6a-kanMX4 [17]. The PCR product
was used to transform the S. cerevisiae strain Superyor. The transformants were
selected on YT-glucose plates containing 200 μg/ml G418 and disruption was
confirmed by PCR analysis.
2.3.2. Construction of Superyor-(His)10
Plasmid pSK-PDR5PPUS was modified to generate plasmid pSK-
PDR5PPΔΔLT as follows: the unique XhoI and SacI sites were first disrupted,
then a SacI–SpeI–SfiI–XhoI–SphI–SmaI–MluI linker was inserted between the
EcoRI and the SpeI sites by using oligonucleotides LINKERY1 and
LINKERY2. Last, the CYC1 transcription terminator was amplified by PCR
using plasmid pYES2 as template and oligonucleotides CYC1DEB and
CYC1FIN as primers, and inserted between the SmaI and MluI sites. A cassette
containing the 3′-end of the YOR1 ORF fused to an Arg–Gly–Ser–(His)6
sequence, followed by the KanR marker and the end of the PDR5 ORF, was
constructed as follows. First, three overlapping PCR fragments were generated :
(i) the last 300 bp of the YOR1ORF were inserted between the HindIII and XhoI
sites of plasmid pBluescript SK+, to give pBS YORCF5′. The latter plasmid was
used as template for a PCR amplification using the YOR1-NOT and YOR2
oligonucleotide primers; (ii) the plasmid pFA6a-kanMX4 was used to amplify
the KanR gene using the YOR3 and YOR4 oligonucleotide primers; (iii) the
plasmid pSK-PDR5PPΔΔLT and the YOR5 and YOR6-XHO oligonucleotide
primers were used to amplify the last 177 bp of the PDR5 ORF. Then, to
assemble the YOR1-(His)6-Kan
R-PDR5 cassette, approximately 50 ng of each
of the three fragments were combined in a PCR reaction mixture and cycled 5
times to join the fragments. Primers YOR1-NOT and YOR6-XHO were then
added and amplification proceeded for 26 cycles. The PCR fragment (1987 bp)
was cut by NotI and XhoI and inserted into pBluescript SK+. The sequence of
the resulting YOR1-(His)6 ORF was verified. To construct strain Superyor-
(His)10, we took advantage of the presence, in the plasmid pBluescript SK+
YOR1-(His)6-Kan
R-PDR5, of a 67 bp XbaI–XbaI fragment overlapping the
stop codon of the YOR1-(His)6 ORF. To modify the C-terminus of Yor1p-(His)6,
we replaced this fragment by another generated by assembly of 6 overlapping
oligonucleotides as follows: 50 pmol of each YOR-EXT-2, YOR-EXT-3, YOR-
EXT-5 and YOR-EXT-6 were first 5′-phosphorylated using polynucleotide 5′-
hydroxyl-kinase (PNK, Roche) for 1 h at 37 °C. After inactivation of PNK for
10 min at 70 °C, 50 pmol of each YOR-EXT-1 and YOR-EXT-4 were added and
the oligonucleotide mixture was denatured at 95 °C for 2 min. The mixture was
then incubated for 2 h at 37 °C with 2 units of T4 DNA ligase (Invitrogen). The
resulting DNA fragment was ligated with XbaI-cut pBluescript SK+ YOR1-
(His)6-Kan
R-PDR5 and the DNA sequence of the produced plasmid was
verified. The XhoI–NotI linearized pBluescript SK+ YOR1-(His)10-Kan
R-
PDR5 was used to transform the S. cerevisiae strain Superyor [15]. The
transformants were selected on YT-glucose plates containing 200 μg/ml G418.
Replacement at the PDR5 locus of YOR1 by the YOR1-(His)10 construct was
verified by PCR analysis. In addition to the tag, the sequence of Yor1p-(His)10
only differs from that of native Yor1p by the insertion of a glycine residue
between the last C-terminal two residues. The C-terminus is Arg–Ser for the
native protein and Arg–Gly–Ser–(His)10 for Yor1p-(His)10.
2.3.3. Construction of Superyor-(His)10-H1423R and -E1392Q
The complete YOR1 ORF was inserted in multicopy plasmid pYES2 by the
gap repair method [18] to give pYOR. The latter plasmid was used as template,
with oligonucleotides YOR-NOT1 and YOR-XBA-XHO as primers, to generate
a PCR fragment containing the last 520 bp of the YOR1 ORF plus the RGS-
(His)10 coding sequence. This fragment was cut by NotI and XhoI and inserted
into pBluescript SK+ to give pBluescript SK+ YOR-NX1. The sequence of the
inserted fragment was verified. Site-directed mutagenesis were achieved in one
step using pBluescript SK+ YOR-NX1 as template and a couple of mutagenic
primers, in PCR reactions using Pfu Turbo DNA polymerase (Stratagene). To
introduce the E1392Q and H1423R mutations, primers YNBD2MUTEQ1/2 and
YNBD2MUTHR1/2 were used, respectively. After thermal cycling, methylated
wild-type DNAwas restricted in the presence of DpnI before transformation of
XL1-Blue cells (Stratagene). The sequence of the whole mutated fragment was
verified in each case. Mutant plasmids were cut by NotI and XbaI, and the insert
was ligated with NotI/XbaI restricted pBluescript SK+ YOR1-(His)6-Kan
R-PDR5. It should be noted that the internal XbaI site is protected by methylation
and is, therefore, resistant to restriction when the latter plasmid is produced in a
dam+ strain. Plasmids pBluescript SK+ YOR1-(His)10-E1392Q-Kan
R-PDR5
and YOR1-(His)10-H1423R-Kan
R-PDR5 digested by XhoI and NotI were used
to transform the S. cerevisiae strain Superyor. The transformants were selected
as above.
2.4. Drug resistance assays
Cells grown at 30 °C in YT-glucose medium were harvested in the
exponential growth phase, washed and diluted in water to obtain samples with
optical densities at 650 nm of 1, 0.1 and 0.01. To determine minimal inhibitory
concentrations (MICs), 5 μl of each sample were spotted onto YT-glucose plates
containing increasing concentrations of the various studied drugs (Table 2), or
onto YT-glycerol plates containing increasing concentrations of oligomycin.
The plates were analysed after 2 days of incubation at 30 °C. By definition, an
MIC value, as shown in Table 2, is the concentration of the drug for which the
cells do not grow any more. MIC regions for each drug were first searched for by
using large drug concentration scales. Next, to refine the MIC value, closer
concentrations of drugs were used. We arranged to assay concentrations around
the MIC that did not differ by a factor greater than 2. Moreover, with each drug,
the experiments were reproducibly performed at least three times. Thus, if a MIC
value was possibly overestimated, the error cannot exceed 50% of the indicated
MIC value.
2.5. Membrane preparation
The S. cerevisiae cells were grown at 30 °C in YT-glucose medium,
harvested in early stationary growth phase and washed in buffer A (50 mMTris–
HCl (pH 8.0), 10% glycerol, 10 mM 2-mercaptoethanol). The pellets were
resuspended at 0.5 g of cells per ml in buffer A supplemented with protease
inhibitors (1 mM phenylmethylsulfonyl fluoride, 0.5 μg/ml aprotinin, 0.5 μg/ml
antipain, 0.5 μg/ml chymostatin, 0.5 μg/ml leupeptin, 0.5 μg/ml pepstatin A,
100 μg/ml benzamidine, 1 μg/ml o-phenanthroline and 6 μg/ml ovomucoid) and
broken with an equal volume of glass beads by vortexing the cells 10×30 s,
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(2000×g for 3 min) and the membrane pellet (20,000×g for 60 min) was
resuspended at 5 mg proteins/ml in buffer A containing 1 M NaCl plus the full
set of protease inhibitors. After centrifugation at 20,000×g for 60 min, the pellet
was resuspended in buffer A.
2.6. ATPase assay
Routinely, initial rates of ATPase activity from 3 μg membrane proteins were
assayed in a final volume of 100 μl at 37 °C in 50 mM Tris–HCl (pH 7.5)
containing 2 mM MgCl2, 10 μM [γ-
32P]ATP (200 Ci/mol), 0.2 mM
(NH4)6Mo7O24, 50 mM KNO3, 5 mM NaN3, 10 μM EDTA, 2% glycerol and
0.2 mMDTT. The reactions were quenched by the addition of 1 ml of a 1.2% (w/
v) suspension of activated charcoal in 50 mM sodium acetate (pH 4.5) plus
0.35% (w/w) perchloric acid. After 5 min of incubation on ice to allow ATP
binding to charcoal, the supernatant was recovered by two successive cen-
trifugations at 20,000×g, for 3 min each. 750 μl of the supernatant containing the
released γ-32P were mixed with 5 ml of scintillation fluid (Pico-Fluor 15 from
Perkin Elmer) and quantified using the LS 6500 Multi-Purpose Scintillation
Counter (Beckman).
To determine the Km and Vmax values for ATP, we measured initial rate of Pi
production as a function of ATP concentration in the assay. The conditions were
as above, except that magnesiumwas 4 mM. In each assay, the amount of [γ-32P]
ATP was fixed at 200 nCi (i. e. ∼440,000 dpm). ATP was varied from 10 μM to
2 mM. The reason why we did not maintain constant the specific activity of ATP
is as follows: radioactive ATP was only ∼97–98% pure according to Perkin
Elmer. As a result, we measured a background signal of ∼6000–10,000 dpm.
Such a background corresponds to radioactivity that is not retained on charcoal
even in the absence of any incubation. Thus, upon an increase in specific
radioactivity at a given total ATP concentration, both the signal and the back-
ground increased in the same ratios, and the accuracy of the assay was not
improved. Under our conditions, at 2 mM ATP, the measured overall signal was
16,000 dpm in 10 min with a background signal of 6000 dpm.
Km and Vmax values were derived from iterative non-linear fits of the
theoretical Michaelis equation to the experimental values, using the Levenberg–
Marquardt algorithm as previously described [19]. Note that in the used
procedure, accuracies on each measurement are taken into account in the
calculation.
2.7. Protein analysis
SDS-PAGE analysis was carried out in 10% polyacrylamide gels using the
Bio-Rad Mini-Protean II electrophoresis cell. Before loading on the gel, samples
were diluted in sample buffer (62.5 mM Tris–HCl, pH 6.8, 1% SDS, 5%
glycerol, 20 mM 2-mercaptoethanol and 0.5 mg/ml bromophenol blue) andFig. 1. Effect of oligomycin (A) and rhodamine B (B) on the growth of S. cerevisiae
glucose medium, harvested in the exponential growth phase, washed and diluted in
respectively. Samples (5 μl) were spotted either onto YT-glucose plates containing
increasing concentrations of oligomycin (A). The plates were left to incubate at 30incubated at 37 °C for 20 min. Protein concentration was determined by the
Bradford assay, using the Bio-Rad Protein Assay kit with BSA as the standard,
in the presence of 0.1% (v /v) Triton X-100.
2.8. Binding of 8-azido-[α-32P]ATP
Membranes (10 μg of protein) were incubated for 20 min in a final volume
of 20 μl at 4 °C in 50 mM Tris–HCl (pH 7.5), containing 2 mM MgCl2, 10%
glycerol and the indicated concentration of 8-azido-[α-32P]ATP (20 Ci/mmol).
The samples were then illuminated with a UV lamp (312 nm, 6×15 W) for 10 s,
dissolved in sample buffer and analysed by SDS-PAGE. After electrophoresis,
gels were colored with Coomassie blue R250, dried and autoradiographed.3. Results
3.1. Drug resistance profile of overexpressed Yor1p
To investigate the drug resistance properties that may be
assigned to Yor1p, we took advantage of the overproduction of
Yor1p by the strain Superyor [15] in a context where the genes
of at least 5 major ABC drug transporters (PDR5, YCF1, SNQ2,
PDR10, PDR11) are deleted. A Superyor-Δyor strain was also
produced by inserting a geneticin resistance cassette in the
chromosome of Superyor cells. The resulting Yor1 protein is
interrupted at residue 583, just inside NBD1. Drug resistance
was assayed by comparing the growth of Yor1p overexpressing
cells to that of Δyor1 cells spotted on plates containing in-
creasing concentrations of the compound under study. Fig. 1
confirms that Yor1p is involved in oligomycin and rhodamine B
resistance. Cells overexpressing Yor1p continued to grow at
concentrations of oligomycin and of rhodamine B over 100 μM
and 5 mM, respectively. In contrast, Δyor1 cells stopped
growing at 0.3 μM oligomycin and 0.2 mM rhodamine B. We
also investigated the susceptibility of Superyor cells to
analogues of rhodamine B and to drugs towards which a
Δyor1 strain had previously displayed increased sensitivity
[20]. Chemical formulas of these molecules are shown in Fig. 2.
Overexpression of Yor1p conferred increased resistance to
rhodamine 6G and to rhodamine 101 (Table 2). With rhodamine
6G, the factor of increase was of the same order of magnitude asstrains Superyor and Superyor-Δyor. Cells were grown at 30 °C in liquid YT-
water, to obtain samples with optical densities at 650 nm of 1, 0.1 and 0.01,
increasing concentrations of rhodamine B (B), or onto YT-glycerol plates with
°C for 2 days.
Fig. 2. Chemical formulas of the various compounds assayed for drug resistance conferred by Yor1p.
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rhodamine 6G is actively extruded from intact yeast cells by
Pdr5p [21]. Thus, since PDR5 is deleted in the Superyor strain,
we may safely conclude that resistance to rhodamine 6G also
involves Yor1p. Yor1p overexpressing cells showed increased
resistance to rhodamine analogues such as erythrosin B. In
agreement with the previous report that Δyor1 cells are sen-
sitive to doxorubicin and tetracycline [20], we observed in-
creased resistance to these drugs of cells overexpressing Yor1p.
We also found that Superyor cells were slightly more resistant
than the Δyor1 cells to ethidium bromide, to eosin Y and to
verapamil, a modulator of mammalian P-glycoprotein ATPase
activity [22] and of GSH transport by MRP1 [23]. On the other
hand, overexpression of Yor1p had no effect against the toxicity
of o-phenanthroline or of fluorescein. Finally, we searched for a
possible involvement of Yor1p in the resistance to cadmium
[14]. The MIC of the metal (30 μM CdCl2 in Table 2) did not
change upon Yor1p overexpression.
3.2. ATPase activity of Yor1p in membranes
In previous studies, to detect a low ATPase activity asso-
ciated to Yor1p, solubilization and partial purification of this
protein were required [15]. In the present study, we made
every effort to minimize contaminant ATPase activities in
membrane preparations. For this purpose, specific inhibitors
of phosphatases and of vacuolar or mitochondrial ATPases(0.2 mM ammonium molybdate, 50 mM KNO3 and 10 mM
NaN3, respectively) were included in the assays. In addition,
membrane fractions were washed in a buffer containing 1 M
NaCl and repelleted. This washing step allowed further
Yor1p-enrichment by eliminating N50% of the proteins
retained in the membrane extract, without loss of Yor1p as
shown in Fig. 3A. SDS-PAGE analysis of membrane
preparations isolated from the Yor1p-deleted strain (Super-
yor-Δyor) and from Superyor shows a band of approximately
170 kDa (the expected Mr of Yor1p is 166,600 Da) in the
Superyor membranes, but not in the Superyor-Δyor ones (Fig.
3B). Relative Yor1p enrichment was estimated at 8–10% of
total membrane proteins by densitometric scanning of the
Coomassie-stained gel.
The ATPase activity was assayed at 37 °C, pH 7.5, by
measuring the release of [32P]-Pi from 10 μM [γ-32P]ATP in the
presence of 2 mM MgCl2 and of several phosphatases and
ATPases inhibitors, as described in Materials and methods
(Fig. 3C). Membrane extracts containing overproduced Yor1p
displayed an ATP hydrolytic activity of 7.2±0.3 nmol of Pi
released per min and per mg membrane proteins. The activity in
extracts from the Yor1p-deleted strain Superyor-Δyor was 4.8±
0.2 nmol Pi min
−1 mg−1. When protein extracts were omitted,
the rate of spontaneous ATP hydrolysis was less than 0.1 pmol
min−1. Using several preparations of Yor1p-depleted or over-
expressing membranes, similar differences in activities were
reproducibly observed.
Fig. 3. (A, B) Coomassie blue-stained SDS-PAGE profiles obtained along the
preparation of Superyor membranes. (A) Lane 1, Membrane pellet from strain
Superyor (20 μg membrane proteins), Lane 2, Supernatant obtained after washing
with a 1 M NaCl solution (12.5 μg proteins), Lane 3, Crude membrane extract
(pellet obtained after the 1 M NaCl wash) from strain Superyor (7.5 μg proteins).
(B) Lane 1, Crude membrane extract from strain Superyor-Δyor (10 μg proteins),
Lane 2, Crude membrane extract from strain Superyor (10 μg proteins). MW,
molecular weight marker. The position of Yor1p is indicated by an arrow. (C)
Time-dependence of the ATPase activity associated to membrane proteins (3 μg)
prepared from Superyor (n) and Superyor-Δyor (x). ATP hydrolysis was
measured at 37 °C in 50 mM Tris–HCl (pH 7.5) containing 10 μM [γ-32P]ATP
(200 Ci/mol), 2 mM MgCl2, 0.2 mM (NH4)6Mo7O24, 50 mM KNO3, 5 mM
NaN3, 10 μM EDTA, 2% glycerol and 0.2 mM DTT. Experimental error is
estimated to be ±10% for each data point. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 4. Expression (A) and drug resistance (B) of the different Yor1p constructs. (A) Co
Superyor-Δyor, Lane 2, membrane extract from strain Superyor, Lane 3, membran
Superyor-(His)10-E1392Q, Lane 5, membrane extract from strain Superyor-(His)10-H
weight marker. The position of Yor1p is indicated by an arrow. (B) Effect of oligom
(His)10, Superyor-(His)10-E1392Q and Superyor-(His)10-H1423R. Legend is as in F
reader is referred to the web version of this article.)
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activities in Superyor and Superyor-Δyor membranes was spe-
cific of Yor1p, we searched for mutations capable of abolishing
ATP hydrolysis by this protein. Structural analyses of bacterial
ABC-transporters MJ0796 [24], HisP [25], and GlcV [26] have
indicated that the conserved Glu residue immediately adjacent
to the conserved “Walker B” Asp residue might play the role of
a catalytic base during ATP hydrolysis. In agreement with this
idea, mutagenesis of this residue to a Gln in either the NBD1 or
the NBD2 of P-gp results in strongly impaired drug transport
and ATPase activities [27,28]. Similar effects are obtained upon
mutation of this Glu in the NBD2 of human MRP1 [29] or in
that of the Bacillus subtilis multidrug transporter BmrA [30]. In
the bacterial histidine permease, another conserved residue, the
histidine belonging to the H-loop, is essential for hydrolysis,
while ATP binding is not impaired [31]. Mutations in the
maltose transporter [32], in the HylB transporter [33] or in
MRP1-NBD2 [34], confirmed that this conserved His is
essential for activity. Therefore, we substituted the putative
catalytic Glu 1392 residue of Yor1p with a non-acidic Gln one
to create the Yor1p-E1392Q mutant. Another mutant having an
arginine residue substituted for His 1423 was called Yor1p-
H1423R. Both mutants were produced in a previously con-
structed histidine-tagged derivative of YOR1 (for details on
the construction of YOR1-(His)10 see Materials and methods).
SDS-PAGE analysis of membrane preparations (Fig. 4A)
showed that the levels of expression of both mutant proteins
are similar to those of native or of His-tagged Yor1p. As ex-
pected, the resistance of both mutants strains towards olig-
omycin was extremely diminished, as compared to that of
Superyor, thus suggesting that translocation of this compound
had become severely impaired (Fig. 4B). On the other hand,
resistance of cells expressing the intact Yor1p-(His)10 derivative
was identical to that of the Superyor cells.
The ATPase activity of Yor1p-(His)10 expressing membranes
(6.8±0.5 nmol Pi min
−1 mg−1) was very close to that measured
in Superyor membrane preparations (7.2±0.3). Upon introduc-
tion of either the E1392Q or the H1423R mutation, the ATPase
activity of Yor1p-(His)10 membranes was reduced (4.9±0.2,omassie blue-stained SDS-PAGE profiles. Lane 1, membrane extract from strain
e extract from strain Superyor-(His)10, Lane 4, membrane extract from strain
1423R. 10 μg of membrane proteins were applied in each well. MW, molecular
ycin on the growth of S. cerevisiae strains Superyor-Δyor, Superyor, Superyor-
ig. 1A. (For interpretation of the references to colour in this figure legend, the
Fig. 5. Inhibition by o-vanadate of the ATPase activity of membrane proteins
(3 μg) prepared from Superyor (n) and Superyor-Δyor (x). The ATPase activity
of 3 μg membrane proteins overexpressing Yor1p was measured for 15 min as in
Fig. 3C, in the presence of increasing concentrations of o-vanadate. The curve
with open circles was calculated as the difference between the values obtained
using Superyor and Superyor-Δyor membrane proteins. Therefore, the curve
describes the inhibition of the ATPase activity of Yor1p by vanadate. O-vanadate
stock solutions were prepared as described [60] and incubated for 2 min at 95 °C
prior to addition to the assays.
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Yor1p-deleted strain (4.8±0.2). These experiments were re-
produced 3 times. We therefore conclude that the difference in
activity between Superyor and Superyor-Δyor extracts was
small (2.4) but specific of Yor1p. Taking into account that
Yor1p represents∼10% of total membrane proteins, the activity
value specific of Yor1p, measured in the presence of 10 μM
ATP, is around 25 nmol of released Pi min
−1 mg−1.
Rates of ATP hydrolysis as a function of ATP concentration
were followed in Superyor and in Superyor-Δyor extracts. In
the two cases, ATPase activity increased with the substrate
concentration. After subtraction of the activity measured with
Superyor-Δyor, the activity of the Superyor extracts could be
fitted to the Michaelis–Menten equation. A Vmax value of 290±
10 nmol Pi min
−1 mg−1 of Yor1p (0.8 s−1) and a Km value for
ATP of 50±8 μM were determined.
3.3. Effect of ATPase inhibitors
In the following experiments, ATP was kept at a concentra-
tion of 10 μM in the assay. Actually, because the Km value is
50 μM, the rate of ATP hydrolysis specific of Yor1p in Superyor
extracts could have been increased by raising the substrate
concentration above 10 μM. However, we observed that the rate
of ATP hydrolysis in the control Superyor-Δyor extracts also
increased with the ATP concentration. Such a behaviour reflects
saturation, by the substrate, of the various ATPases present in the
Δyor extracts. As a consequence, the ratio between the activities
in the Superyor and Superyor-Δyor extracts slightly decreased
when the ATP concentration was raised. This decrease was at the
expense of the accuracy of the assay. Thus, to optimize accuracy
while being under steady-state conditions, we chose an ATP
concentration below the Km value.
Several ATPase inhibitors were screened for their effect on the
activity of both Superyor and Superyor-Δyor extracts (Table 3).
Thiol reagents, such as p-chloromercuryphenyl sulfonate
(200 μM) or N-ethylmaleimide (up to 2 mM), slightly inhibited
Δyor or Superyor membrane ATPase activities. Ouabain
(1 mM), an Na+, K+-ATPase inhibitor, di-cyclohexylcarbodii-
mide (100 μM), an F-ATPase inhibitor, and heparin (1 mg/ml), a
kinase inhibitor, had no effect on either activities. The effect ofTable 3
Effects of various compounds on the activity of Superyor and Superyor-Δyor
membranes
ATPase activity (nmol Pi min
−1 mg−1)
Superyor-ΔYor Superyor
Control 4.8±0.2 7.2±0.3
pCMPS, 200 μM 4.2±0.2 6.1±0.1
NEM, 2 mM 3.7±0.3 5.6±0.2
Ouabain, 1 mM 4.6±0.1 7.1±0.3
DCC, 100 μM 4.7±0.2 6.6±0.2
Heparin, 10 μM 4.5±0.1 6.4±0.2
Vanadate, 200 μM 1.9±0.2 2.2±0.3
The ATPase activity of 3 μg membrane proteins was followed for 15 min in the
presence of 2 mM MgCl2, as described in Materials and methods. The
compounds under study were added in the assays at the concentrations indicated
in the table. Data correspond to the mean±SD of three independent experiments.vanadate, a specific inhibitor of P-ATPases and ABC-transpor-
ters, is shown in Fig. 5. The activity measured in Superyor-Δyor
membranes was sensitive to the presence of this inhibitor. At
200 μM vanadate, 60% of the ATPase activity was lost. With
Yor1p overexpressing membranes, the ATPase activity was also
strongly inhibited by vanadate. After subtraction of the Superyor-
Δyor values (Fig. 5, open circles), the ATPase activity specific of
Yor1p is shown to be inhibited by more than 90% upon saturation
by vanadate, with an IC50 around 20 μM.
3.4. Effect of drugs
Substrate-stimulated ATPase activity of membranes expres-
sing ABC-transporters has been reported in several cases. For
instance, the ATPase activity of mammalian P-gp in membrane
preparations is stimulated by up to 5-fold upon addition of
verapamil [35,36]. In contrast, oligomycin, a potential substrate
of Yor1p, inhibits the ATPase activity of partially purified
Yor1p [15]. In the present study, we used membrane extracts to
investigate the effects of drugs towards which cells over-
expressing Yor1p exhibit increased resistance. As shown in
Fig. 6, none of the assayed compounds succeeded in stimulating
the ATPase activity of Yor1p. Instead, nearly 95% of the Yor1p
specific ATPase activity was inhibited by oligomycin, with an
IC50 of 6.9±1.4 μM. Nearly full inhibitions by rhodamine 6G
(IC50=1.2±0.2 μM), rhodamine B (IC50=5.9±0.5 μM), rho-
damine 101 (IC50=1.1±0.2 μM), verapamil (IC50=42±
12 μM) and doxorubicin (IC50=73±5 μM) were also observed.
The ATPase activities of Superyor-Δyor membrane prepara-
tions were measured, in parallel, in the presence of the above
drugs. In all cases, the assayed drug did not inhibit the activity
by more than 10%.
Fig. 6. Effect of potential substrates on the ATPase activity of membrane-bound
Yor1p. The ATPase activity of 3 μg membrane proteins overexpressing Yor1p
was measured as in Fig. 3C, in the presence of increasing concentrations of
indicated drugs. Rate values with membranes prepared from the Δyor1 strain
were measured in parallel and subtracted. Data are presented as percentages of
control activity (100%) assayed in the absence of any drug. Oligomycin,
rhodamine 6G and rhodamine 101 were assayed in the additional presence of 2%
ethanol to ensure solubilization of these drugs.
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cin was used as model “substrate”. First, to exclude the pos-
sibility that this drug may cause denaturation of the protein, we
preincubated Yor1p expressing membranes in the presence of a
nearly half-inactivating concentration of oligomycin (5 μM).
After addition of the drug, ATPase hydrolysis was followed
over time, for a period of 2 h. No further inhibition of Yor1p
hydrolytic activity was observed in these conditions. Another
explanation might be that oligomycin prevents the binding of
ATP to the NBDs. Indeed, disulfiram, a modulator of P-gp and
of MRP1 impairs the binding of ATP [37]. Therefore, we
searched for an effect of oligomycin on the binding of 8-azido-
[α-32P]ATP, a photoaffinity analog of ATP, which has been
extensively used to probe the nucleotide binding sites of other
ABC-transporters. Membrane preparations were incubated for
20 min on ice with 2 mM MgCl2 and with 5 or 10 μM of the
reagent. The samples were analysed by SDS-PAGE and auto-
radiographed. The intensity of Yor1p labelling was higher with
10μM8-azido-ATP thanwith 5μM.We therefore concluded that,
at 5μMof the reagent, (i) the binding site for 8-azido-ATPwas not
saturated and (ii) the labelling reaction was not completed during
the time of the assay. Next, we designed a sensitive assay
containing a 5 or 1 μM fixed concentration of 8-azido-ATP and
variable ATP concentrations to verify that the two nucleotides
were in competition to bind Yor1p. As expected, excess ATP
cancelled the reaction of the photo-reagent. The same assay, with
variable oligomycin concentrations (up to 100 μM) instead of
ATP, was used to search for a possible interference of oligomycin
with the binding of 8-azido-ATP to Yor1p. The result was neg-
ative. Thus, inhibition by oligomycin of the ATPase activity of
Yor1p cannot be explained by an interference of this drugwith the
ATP binding capacity of the NBDs.4. Discussion
4.1. Substrate specificity of Yor1p
Yor1p was initially identified on the basis of its ability to
elevate oligomycin resistance when it was overproduced from
a high-copy-number plasmid [13]. At the same time, Cui et al.
showed that Yor1p was important to confer tolerance to
organic anions that contain carboxyl groups [14]. As
oligomycin does not contain anionic groups, the latter authors
speculated that this drug might be modified in vivo into a
compound containing a carboxyl group or that it might be
pumped out as an anionic conjugate. However, Yor1p was later
implicated in the resistance to aureobasidin A, an antifungal
antibiotic which structure is that of a cyclic depsipeptide [38]. In
this study, we show that overexpression of Yor1p increases the
cellular resistance to the P-glycoprotein modulator verapamil
and to cyclic compounds that do not possess a carboxyl group,
like doxorubicin or tetracycline. Moreover, we observe that the
Superyor strain is more resistant than the Δyor1 strain to
rhodamine 6G, a non-anionic analogue of rhodamine B.
Therefore, like yeast Pdr5p [21] or mammalian P-glycoprotein
[39], Yor1p confers resistance to a broad range of structurally
unrelated molecules.
We find that overexpression of Yor1p is accompanied by
increased resistance to rhodamine 6G. However, upon deletion
of YOR1, the sensitivity of yeast cells to this drug was not
changed [20]. Possibly, the expression in yeast of the products
of other multidrug-resistance genes trans-dominate an effect of
Yor1p on the transport of rhodamine 6G. Here, because of its
large overexpression, Yor1p can be shown to be involved. Such
a situation is reminiscent of the resistance to camptothecin
which is principally mediated by Snq2p. Deletion of PDR5 or
of YOR1 had little effect on camptothecin sensitivity. Yet,
overexpression of Pdr5p increased the resistance of yeast to this
drug [40].
In subclass II.1, Yor1p is homologous to Ycf1p which is
involved in cadmium resistance [11]. Thus, an overlapping
substrate specificity of the two transporters is a possibility. In
agreement with this idea, earlier studies showed that Δyor1
cells were more sensitive to cadmium than the parental cells
[14]. More recently, various Yor1p-deleted or overproducing
strains were compared [41]. It was shown that, in the presence
of a functional Ycf1p, deletion of Yor1p did not increase
cadmium toxicity and that overexpression of Yor1p conferred
only limited resistance to cadmium. Actually, growth at low
temperature was required to evidence such a resistance. Thus,
even though Yor1p has resemblance with Ycf1p, its role in
cadmium detoxification appears reduced. Here, by growing
cells in rich medium at 30 °C, we did not succeed in showing an
effect of Yor1p on the resistance against cadmium.
The case of verapamil also deserves discussion. We show in
this study that Yor1p confers slight but significant resistance
against this alkaloid. This suggests that intact or modified
verapamil is a substrate of Yor1p. In favour of this idea, the
ATPase activity of the ABC-transporter in membrane prepara-
tions is inhibited with a verapamil IC50 of ∼50 μM. Verapamil
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and MRP1 [23]. In the latter case, indirect action of verapamil
on the GSH status of the cells has been proposed, rather than
direct competition of verapamil for the MRP1 substrate binding
site. Thus, distinct modes of action of verapamil on MRP1 and
Yor1p functions can be ascribed to the fact that Ycf1p, not
Yor1p, is the functional homologue of MRP1 in yeast.
4.2. ATPase activity of Yor1p in membrane preparations
In this study, we characterized the ATPase activity of
Yor1p in membrane enriched extracts. Detection of an ATPase
activity specific for the presence of Yor1p required a step of
washing at high ionic force. This procedure allowed a further
two-fold enrichment of the membranes in Yor1p. Care was
taken to minimize contaminant ATPase activities by including
to the solutions several inhibitors specific of vacuolar and
mitochondrial ATPases and of phosphatases. In these
conditions, a basal ATPase activity of 0.8 s−1, specific of
Yor1p, could be measured. Attribution of this activity to
Yor1p is supported by the fact that mutations of essential
residues in NBD2 reduced the value of the rate of ATP
hydrolysis by membranes overexpressing Yor1p to that by
Δyor membranes. Moreover, the Yor1p ATPase activity
which we report here (Vmax=300 nmol min
−1 mg−1) is
comparable to that previously measured (Vmax=500 nmol
min−1 mg−1) with a solubilized and partially purified Yor1p
sample [15]. It is difficult to compare Vmax of different ABC
proteins in membrane preparations, as assay conditions are
variable and overproduction levels are not often indicated.
However, the Yor1p activity given here is at least 10 times
lower than that of yeast membrane-bound Pdr5p (5 μmol
min−1 mg−1 of Pdr5p) measured in similar conditions [43], or
than that of overproduced Chinese hamster P-glycoprotein
(4–9 μmol min−1 mg−1 of P-gp) in its native membrane
environment [35]. Contrasting with its low ATPase activity,
Yor1p displays a Km value for ATP of 50 μM, one order of
magnitude smaller than the Km of membrane-bound Pdr5p
(0.5 mM) or of Chinese hamster P-gp (1.3 mM). Low ATPase
activities coupled to high affinities for the nucleotide have
been reported for purified MRP1 [44] and CFTR [45], both of
which are members of the ABCC subfamily. It is noteworthy
that, in contrast with many other ABC proteins, the ABCC-
proteins are characterized by relatively divergent NBDs.
Alignment of the primary sequence of CFTR with those of
other ABC-transporters shows that several highly conserved
residues in NBDs are not conserved in CFTR NBD1.
Actually, the NBDs of other ABCC family members also
show asymmetric sequence abnormalities, like those in CFTR.
In the case of Yor1p, the conserved glutamine of the Q-loop
in NBD1 is missing. Several studies report different
behaviours of the ABCC's NBD1 and NBD2, in particular
at the level of ATP binding and hydrolysis [46–49]. It has
been suggested that, in CFTR and MRP1, NBD1 binds ATP
with high affinity but sustains little hydrolysis, whereas
NBD2 is hydrolytically active [50,51]. Thus, a slow release of
the bound nucleotide from NBD1 could account for the ratherlow ATPase activity values associated to the ABCC subfamily
members.
4.3. Effect of potential substrates
Substrate-stimulated ATPase activity has been observed by
using plasmamembrane preparations as well as proteoliposomes-
reconstituted purified ABC-transporters [35,36,44,52,53]. It was,
therefore, surprising to find that ATP hydrolysis by membrane-
bound Yor1p is inhibited rather than stimulated by the presence
of its potential substrates. Yet, the observation of an inhibition
clearly indicates that these compounds interact with Yor1p. Inhi-
bition of the ATPase activity of Pdr5p has previously been
reported [54–56]. In the case of flavonoids, a partial overlap of the
drug and of the nucleotide binding sites was invoked to account
for the inhibition of Pdr5p activity [54]. Here, we show that, at
least in the case of oligomycin, binding of the drug does not hinder
that of the nucleotide. Therefore, inhibition of Yor1p ATPase
activity by oligomycin does not simply result from a competition
with ATP at the nucleotide binding site.
Failure to detect a drug-stimulation of the ATPase activity
of an ABC-protein has already been reported. This is, for
instance, the case of Candida albicans Cdr1p, a Pdr5p
homolog, obtained upon overexpression in the same host S.
cerevisiae strain as the one used here [57]. This is also the
case of the human ABCG2 transporter expressed in insect
cells. In the latter case, ATP hydrolysis could not be
stimulated by any of the potential substrates that were
assayed. An inhibition of the ATPase activity was even
observed in the presence of Hoechst 33342, a transported
substrate of ABCG2 [58]. This behaviour was explained by
assuming the presence in the membrane preparations of an
unknown ABCG2 substrate that would ensure maximal rate of
ATP hydrolysis. Therefore, competition between this endog-
enous activator and any added substrate would lead either to
conservation, at best, or to reduction of the rate of ATP
hydrolysis. Another explanation may be that preparation of the
membranes has removed an unknown molecule that is
required for ATPase powered translocation. In the absence
of such a co-factor, a substrate would still bind Yor1p but the
basal ATPase catalytic cycle of the transporter would be
blocked. For instance, uptake of vincristine by MRP1-enriched
inside-out membrane vesicles is stimulated by the presence of
reduced glutathione [59]. Actually, we searched whether the
addition of GSH interfered with the ATPase activity of
Superyor membranes but could not evidence an effect (results
not shown). Finally, we note that, up to now, transport of
drugs by Yor1p could be evidenced only in vivo [15].
Therefore, modifications of the Yor1p substrates inside the cell
or co-transport with an, as yet undiscovered, molecule cannot
be excluded.
To further investigate the relationship between substrate
transport and ATP hydrolysis, Yor1p function will have to be
analysed in defined environments. To this end, the Superyor
strain was used to produce a Yor1p derivative with a C-terminal
histidine-tag. As shown here, this additional sequence neither
compromises the overexpression nor the hydrolytic properties
77I. Grigoras et al. / Biochimica et Biophysica Acta 1778 (2008) 68–78of Yor1p. Experiments are underway to solubilize tagged-Yor1p
and to isolate it, while keeping intact its ATPase activity.
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